Objective To investigate the influence of individual factors and labor organization factors on work-related musculoskeletal disorders (WMSDs) in automobile manufacturing workers, and to provide a scientific basis for the prevention and treatment of WMSDs in automobile manufacturing workers. Methods In April 2020, 5564 workers in an automobile factory were selected by cluster sampling method. The prevalence of WMSDs was investigated by using the Musculoskeletal Disorders Questionnaire, and the influence of individual factors and labor organization factors on WMSDs was investigated by using generalized estimation equation. Results The prevalence rate of WMSDs was 79.00% (4396/5564), and the prevalence rate of multisite WMSDs was 67.95% (3781/5564). The analysis of generalized estimation equation showed that doing the same job every day (OR= 1.478, P < 0.05), age ≥40 years (OR=1.416, P< 0.05), personnel shortage (OR= 1.356, P < 0.05), and work length of 6～10 years and 11～15 years (OR= 1.349, P< 0.05) were the main risk factors for WMSDs in automobile manufacturing workers. Shift work and working time > 40 hours per week increased the risk of WMSDs (P< 0.05). Male and adequate rest time were protective factors for WMSDs. The job correlation matrix showed that WMSDs in most parts had a positive correlation. Conclusions The prevalence of multisite WMSDs of workers in automobile manufacturing industry is high, and unreasonable labor organization is the main risk factor of WMSDs. Appropriate work breaks can effectively reduce the risk of WMSDs, and effective intervention measures should be carried out to prevent the occurrence of WMSDs in workers in automobile manufacturing industry. The generalized estimation equation can better analyze the influencing factors of WMSDs.

Objective:To explore the risk signals of montelukast-related adverse events (AEs) in pediatric patients and provide reference for the safe use.Methods:AE reports of children with montelukast as the primary suspect drug from the first quarter of 2004 to the third quarter of 2022 were collected by searching the US FDA Adverse Event Reporting System database (FAERS). AEs were standardized and classified according to the preferred terms (PT) and system organ class (SOC) of Medical Dictionary for Regulatory Activities 23.0. Proportional reporting odds ratio (PRR) method was used to mine the AE risk signals of montelukast. An AE with reports ≥3, PRR≥2, and χ2>4 was defined as a positive signal, which were analyzed using descriptive method. Results:A total of 5 179 AE reports were included in the analysis, involving 1 295 PTs, and 233 positive PTs were obtained by PRR method. The top 10 PTs in AE reports were aggressive behavior, anxiety, suicidal ideation, abnormal behavior, depression, anger, nightmares, insomnia, crying loudly and night terrors. Except crying loudly, all of them were adverse reactions recorded in the label. The top 10 PTs in signal intensity were sensory overload, arrhythmia, separation anxiety disorder, loneliness phobia, dust allergy, Mille-Fisher syndrome, eosinophilic granuloma complicated with polyangitis, personality disorder in children, night terrors and decreased platelet adhesion. Among them, abnormal heart rate, Mille-Fisher syndrome and decreased platelet adhesion were not recorded in the label. A total of 59 of the 233 positive PTs were not recorded in the label, involving 10 SOCs. The top 5 SOCs were social environment, mental illness, injury, poisoning and surgical complications, general conditions and administration site, and respiratory, thoracic and mediastinal diseases.Conclusion:The main AEs of pediatric patients receiving montelukast treatment in the US FAERS are aggressive behavior, anxiety, depression, insomnia, night terrors, etc., all of which are adverse reactions recorded in the label; adverse reactions not recorded in the drug label include abnormal heart rate, Miller-Fisher syndrome, and decreased platelet adhesion.

Objective:To explore the risk signals of montelukast-related adverse events (AEs) in pediatric patients and provide reference for the safe use.Methods:AE reports of children with montelukast as the primary suspect drug from the first quarter of 2004 to the third quarter of 2022 were collected by searching the US FDA Adverse Event Reporting System database (FAERS). AEs were standardized and classified according to the preferred terms (PT) and system organ class (SOC) of Medical Dictionary for Regulatory Activities 23.0. Proportional reporting odds ratio (PRR) method was used to mine the AE risk signals of montelukast. An AE with reports ≥3, PRR≥2, and χ2>4 was defined as a positive signal, which were analyzed using descriptive method. Results:A total of 5 179 AE reports were included in the analysis, involving 1 295 PTs, and 233 positive PTs were obtained by PRR method. The top 10 PTs in AE reports were aggressive behavior, anxiety, suicidal ideation, abnormal behavior, depression, anger, nightmares, insomnia, crying loudly and night terrors. Except crying loudly, all of them were adverse reactions recorded in the label. The top 10 PTs in signal intensity were sensory overload, arrhythmia, separation anxiety disorder, loneliness phobia, dust allergy, Mille-Fisher syndrome, eosinophilic granuloma complicated with polyangitis, personality disorder in children, night terrors and decreased platelet adhesion. Among them, abnormal heart rate, Mille-Fisher syndrome and decreased platelet adhesion were not recorded in the label. A total of 59 of the 233 positive PTs were not recorded in the label, involving 10 SOCs. The top 5 SOCs were social environment, mental illness, injury, poisoning and surgical complications, general conditions and administration site, and respiratory, thoracic and mediastinal diseases.Conclusion:The main AEs of pediatric patients receiving montelukast treatment in the US FAERS are aggressive behavior, anxiety, depression, insomnia, night terrors, etc., all of which are adverse reactions recorded in the label; adverse reactions not recorded in the drug label include abnormal heart rate, Miller-Fisher syndrome, and decreased platelet adhesion.

A 1-year and 4 month-old boy with epilepsy received sodium valproate oral solution 2.5 ml twice daily, Shengxue Tiaoyuan decoction (升血调元汤) 6 ml twice daily and five vitamins and calcium gluconate oral solution 3 ml twice daily. On day 13 of treatments, the boy developed red maculopapular rashes and blisters all over the body, some of which fused into pieces; his bilateral conjunctiva slightly congested with secretions, mouth and lip mucosa congested and eroded, and a few maculopapular rashes appeared on the external genitalia. At the same time, the boy′s body temperature rose up to 40.0 ℃. Stevens-Johnson syndrome was diagnosed, which was considered to be related to sodium valproate oral solution. The drug was stopped immediately and treatments such as blood perfusion, infusion of plasma and red blood cells, anti-infection and hormone therapy, and eye and skin care were given. On the 17th day of treatments after drug withdrawal, the rashes on the whole body subsided, ulceration scabbed, erosion of oral and lip mucosa cured, and conjunctival congestion disappeared.

A 1-year and 4 month-old boy with epilepsy received sodium valproate oral solution 2.5 ml twice daily, Shengxue Tiaoyuan decoction (升血调元汤) 6 ml twice daily and five vitamins and calcium gluconate oral solution 3 ml twice daily. On day 13 of treatments, the boy developed red maculopapular rashes and blisters all over the body, some of which fused into pieces; his bilateral conjunctiva slightly congested with secretions, mouth and lip mucosa congested and eroded, and a few maculopapular rashes appeared on the external genitalia. At the same time, the boy′s body temperature rose up to 40.0 ℃. Stevens-Johnson syndrome was diagnosed, which was considered to be related to sodium valproate oral solution. The drug was stopped immediately and treatments such as blood perfusion, infusion of plasma and red blood cells, anti-infection and hormone therapy, and eye and skin care were given. On the 17th day of treatments after drug withdrawal, the rashes on the whole body subsided, ulceration scabbed, erosion of oral and lip mucosa cured, and conjunctival congestion disappeared.

Mercaptopurine is used to treat children with acute lYmphoblastic leuKemia. Mercaptopurine can cause bone marrow suppression and liver toxicitY,threatening the lives of children, resulting in interruption or discontinuation of the chemotherapY,increasing the risK of disease recurrence. The mercaptopurine dosage regimens should be adjusted according to drug metabolizing enzYme genotYpes, detection of intra-erYthrocYtic metabolic products, and creating a phYsical model. Individualized administration should be adopted in order to improve the efficacY and safetY of mercaptopurine.

Mercaptopurine is used to treat children with acute lYmphoblastic leuKemia. Mercaptopurine can cause bone marrow suppression and liver toxicitY,threatening the lives of children, resulting in interruption or discontinuation of the chemotherapY,increasing the risK of disease recurrence. The mercaptopurine dosage regimens should be adjusted according to drug metabolizing enzYme genotYpes, detection of intra-erYthrocYtic metabolic products, and creating a phYsical model. Individualized administration should be adopted in order to improve the efficacY and safetY of mercaptopurine.